Ariad raises $300M, plots big HQ move in Cambridge; Kirk bets on Transgenomic

 @FierceBiotech: AstraZeneca kicks tires on respiratory program ditched by J&J. Story | Follow @FierceBiotech

@JohnCFierce: Cowen's Ed Nash is predicting '16 arrival of Sarepta's eteplirsen, with $263M start Question about accelerated OK. Personally I'm doubtful. | Follow @JohnCFierce

@RyanMFierce: IBM touts push into #biotech with bug-busting gel. Should we care yet? Report | Follow @RyanMFierce

> Ariad Pharmaceuticals ($ARIA) has priced a $300 million stock offering to fund the marketing of its leukemia drug ponatinib and other expenses. Item. Also, the company has signed a lease on 244,000 square feet of office and lab space in Cambridge, MA, where it is now headquartered. The lease is on space in a yeat-to-be-completed building from Alexandria Real Estate Equities. Deal

> Transgenomic is raising $8.3 million in a private placement with biotech billionaire Randal Kirk's Third Security and other investors. Release

> Seattle Genetics ($SGEN) spotlighted some early signs of safety and efficacy form a early-stage study of its antibody-drug conjugate called ASG-5ME in metastatic pancreatic ductal adenocarcinoma. Release

Medical Device News

 @FierceMedDev: Spiking costs blunt Covidien's strong sales quarter. News | Follow @FierceMedDev

 @DamianFierce: Dx company LipoScience is going public, targeting a $40M IPO as $LPDX. Report | Follow @DamianFierce

> ResMed posts 24% income jump in another big quarter. Article

> iRobot spikes on the Street after FDA OK. Story

Pharma News

@FiercePharma: Merrill Lynch high on Bayer: The company made its list of top Euro-stocks, thanks to new drugs/pipeline. More | Follow @FiercePharma

 @AlisonBFierce: Feds OK Novavax's experimental flu vaccine program. News | Follow @AlisonBFierce

> Groups lobby White House as sunshine rule lingers. Report

> Novartis faces probes on Tekturna tactics, Iran sales. News

And Finally… U.S. researchers say that patients with hepatitis C virus are almost four times as likely to have a tattoo, linking body art to the leading cause of liver cancer, Reuters reported. Article

 

 

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.